Bob Butchofsky to Speak at Ocular Drug Discovery Meeting, March 2014, San Diego

San Diego, CA (PressExposure) November 27, 2013 -- Bob Butchofsky, President and CEO of Mati Therapeutics will present on "An Alternative to Eye Drops - Minimally Invasive Sustained Drug Delivery for Glaucoma" at GTC's 6th Annual Ocular Diseases & Drug Discovery Conference held on March 20-21, 2014 in San Diego, CA.

Mati Therapeutics is developing a drug delivery platform technology using a drug eluting punctual plug to deliver medications to the anterior segment of the eye. The first disease target is glaucoma, where the literature shows that 50% of patients do not adhere to their eye drop therapy beyond the first 6 months. The first product Mati has under development, currently in Phase II trials, is latanoprost. Previous Phase II trials have identified the dosing and Mati is currently evaluating a latanoprost punctal plug to timolol eye drops. The Phase II trial is expected to be completed in 2014. The talk will highlight the current status of the Phase II trials and discuss the benefits of this minimally invasive approach, which could be an alternative to eye drop therapy for glaucoma.

Robert L. Butchofsky II is currently the Founder and CEO of Mati Therapeutics. Headquartered in Austin, Texas, Mati is developing a non-invasive sustained drug delivery platform to treat ocular diseases, in particular glaucoma. Mr. Butchofsky is the former President and CEO of QLT Inc., a publicly traded Vancouver-based biotech company focused on ocular diseases and the company responsible for the first medical treatment for age related macular degeneration, Visudyne®. From June 1990 to August 1998, Mr. Butchofsky was employed at Allergan Inc., a pharmaceutical company, where he built an extensive background with ocular pharmaceutical products and Botox(r), including sales, health economics, worldwide medical marketing, and product management. Prior to joining Allergan Inc.,

Mr. Butchofsky spent several years managing clinical trials at the Institute for Biological Research and Development. Mr. Butchofsky has over 20 years of commercial and development experience in ophthalmology. He received the Visionary Award from the Foundation Fighting Blindness for his commitment to preserving vision. Mr. Butchofsky also serves as Chairman of the Board of Superna Life Sciences Inc., a privately-held pharmaceutical company located in Vancouver, British Columbia. He is also Chairman of CDRD Ventures, the commercial vehicle for the Centre for Drug Research and Development, Canada's drug development and commercialization center.

The Ocular Diseases & Drug Discovery Conference continues to promote the discovery of ocular disease by offering presentations on novel and innovative therapeutics in ocular drug development and discovery. The conference brings together leading scientists, researchers and experts to discuss and collaborate on the latest research and development, safety assessment, regulatory issues and drugs in development for combating and curing age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, DME, uveitis and other ocular diseases.

For more information, please visit

About GTC Conferences

GTC organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic institutions, government organizations and the financial community.

GTC (Global Technology Community), LLC, is a privately held company founded in 2002.

Press Release Source:

Press Release Submitted On: November 27, 2013 at 12:43 am
This article has been viewed 31488 time(s).